Skip to main content

Advertisement

SpringerLink
Log in

Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions

  • Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

While isotretinoin has been the gold-standard of therapy for severe acne since its approval in 1982, its anti-inflammatory properties makes it a potentially applicable and versatile therapy for a wide variety of dermatologic conditions yet to be explored. This systematic review comprehensively recounts the success of oral isotretinoin in non-acne cutaneous diseases and provide insight into future directions of isotretinoin utility. A systematic literature review was performed using PubMed. Search terms included “isotretinoin” OR “accutane” AND “skin” OR “dermatology” OR “hair” OR “nails” OR “rosacea” OR “psoriasis” OR “pityriasis rubra pilaris” OR “condyloma acuminata” OR “granuloma annulare” OR “darier’s disease” OR “non-melanoma skin cancer” OR “frontal fibrosing alopecia” OR “cutaneous lupus erythematosus” OR “hidradenitis suppurativa” OR “photodamaged skin” OR “skin aging” OR “wart” OR “flat warts” OR “plane warts” OR “lichen planus” OR “dissecting cellulitis” OR “folliculitis decalvans” OR “sebaceous hyperplasia” OR “cutaneous t-cell lymphoma” OR “mycosis fungoides.” A total of 169 studies discuss the use of oral isotretinoin for 16 non-acne dermatologic conditions, the most common being non-melanoma skin cancers (0.2–8.2 mg/kg/day), cutaneous T-cell lymphomas (0.5–2 mg/kg/day), and rosacea (0.22–1 mg/kg/day). Inflammatory conditions such as rosacea, granuloma annulare, and hidradenitis suppurativa benefit from lower oral isotretinoin dosage of 0.3–1 mg/kg/day, whereas, hyperkeratotic diseases such as psoriasis and pityriasis rubra pilaris, consistently respond better to higher dosages of up to 2–4 mg/kg/day for lesion clearance. Recurrence of disease following discontinuation of isotretinoin have been reported for rosacea, psoriasis, granuloma annulare, Darier’s disease, dissecting cellulitis, and non-melanoma skin cancers. Disease exacerbation was reported in some patients with hidradenitis suppurativa. Off-label isotretinoin is an effective treatment choice for dermatological conditions beyond acne. Further prospective, randomized human trials are needed to clarify when and how to prescribe off-label isotretinoin for maximum efficacy and safety.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Layton A (2009) The use of isotretinoin in acne. Dermatoendocrinology 1(3):162–169

    CAS  Google Scholar 

  2. King K, Jones DH, Daltrey DC, Cunliffe WJ (1982) A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 107(5):583–590

    CAS  PubMed  Google Scholar 

  3. Wysowski DK, Swann J, Vega A (2002) Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 46(4):505–509

    PubMed  Google Scholar 

  4. Chen J, White T, Juzba M, Chang E (2002) Oral isotretinoin: an analysis of its utilization in a managed care organization. J Manag Care Spec Pharm 8(4):272–277

    Google Scholar 

  5. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53(3):358–388

    CAS  PubMed  Google Scholar 

  6. Layton AM, Dreno B, Gollnick HP, Zouboulis CC (2006) A review of the European Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 20(7):773–776

    CAS  PubMed  Google Scholar 

  7. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H et al (1984) Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 10(3):490–496

    CAS  PubMed  Google Scholar 

  8. Bollag W (1972) Prophylaxis of chemically induced benign and malignant epithelial tumorsby vitamin A acid (retinoic acid). Eur J Cancer 8:689–693

    CAS  PubMed  Google Scholar 

  9. Huen AO, Kim EJ (2015) The role of systemic retinoids in the treatment of cutaneous T cell lymphoma. Dermatol Clin 33(4):715–729

    CAS  PubMed  Google Scholar 

  10. Boer J, van Gemert MJ (1999) Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 40(1):73–76

    CAS  PubMed  Google Scholar 

  11. Recchia F, De Filippis S, Rosselli M, Saggio G, Fumagalli L, Rea S (2002) Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study. Int J Oncol 20(6):1275–1282

    CAS  PubMed  Google Scholar 

  12. Vollberg TM Sr, Nervi C, George MD, Fujimoto W, Krust A, Jetten AM (1992) Retinoic acid receptors as regulators of human epidermal keratinocyte differentiation. Mol Endocrinol 6(5):667–676

    CAS  PubMed  Google Scholar 

  13. Group OLoEW (2011) The Oxford 2011 Levels of Evidence. [cited; Available from: https://www.cebm.net/index.aspx?o=5653

  14. Bagheri MM, Safai B (2001) Cutaneous malignancies of keratinocytic origin. Clin Dermatol 19(3):244–252

    CAS  PubMed  Google Scholar 

  15. Nickle SB, Peterson N, Peterson M (2014) Updated physician’s guide to the off-label uses of oral isotretinoin. J Clin Aesthet Dermatol 7(4):22–34

    PubMed  PubMed Central  Google Scholar 

  16. Goldberg LH, Hsu SH, Alcalay J (1989) Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol 21(1):144–145

    CAS  PubMed  Google Scholar 

  17. Peck GL, Gross EG, Butkus D, DiGiovanna JJ (1982) Chemoprevention of basal cell carcinoma with isotretinoin. J Am Acad Dermatol. 6(4 Pt 2 Suppl):815–823

    CAS  PubMed  Google Scholar 

  18. Peck GL, DiGiovanna JJ, Sarnoff DS, Gross EG, Butkus D, Olsen TG et al (1988) Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 19(1 Pt 2):176–185

    CAS  PubMed  Google Scholar 

  19. Sollitto RB, DiGiovanna JJ (1996) Failure of interferon alfa and isotretinoin combination therapy in the nevoid basal cell carcinoma syndrome. Arch Dermatol 132(1):94–95

    CAS  PubMed  Google Scholar 

  20. Toma S, Palumbo R, Vincenti M, Aitini E, Paganini G, Pronzato P et al (1994) Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. Ann Oncol 5(5):463–465

    CAS  PubMed  Google Scholar 

  21. Lippman SM, Meyskens FL Jr (1987) Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107(4):499–502

    CAS  PubMed  Google Scholar 

  22. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM et al (1992) 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84(4):235–241

    CAS  PubMed  Google Scholar 

  23. Meyskens FL Jr, Gilmartin E, Alberts DS, Levine NS, Brooks R, Salmon SE et al (1982) Activity of isotretinoin against squamous cell cancers and preneoplastic lesions. Cancer Treat Rep 66(6):1315–1319

    PubMed  Google Scholar 

  24. Skroza N, Proietti I, Tolino E, Bernardini N, La Viola G, Nicolucci F et al (2014) Isotretinoin for the treatment of squamous cell carcinoma arising on an epidermoid cyst. Dermatol Ther 27(2):94–96

    PubMed  Google Scholar 

  25. Bellman BA, Eaglstein WH, Miller J (1996) Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation 61(1):173

    CAS  PubMed  Google Scholar 

  26. Feldman RJ, Maize JC (2007) Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol 46(1):77–79

    PubMed  Google Scholar 

  27. Haydey RP, Reed ML, Dzubow LM, Shupack JL (1980) Treatment of keratoacanthomas with oral 13-cis-retinoic acid. N Engl J Med 303(10):560–562

    CAS  PubMed  Google Scholar 

  28. Levine N, Miller RC, Meyskens FL Jr (1984) Oral isotretinoin therapy. Use in a patient with multiple cutaneous squamous cell carcinomas and keratoacanthomas. Arch Dermatol 120(9):1215–1217

    CAS  PubMed  Google Scholar 

  29. Shaw JC, White CR Jr (1986) Treatment of multiple keratoacanthomas with oral isotretinoin. J Am Acad Dermatol 15(5 Pt 2):1079–1082

    CAS  PubMed  Google Scholar 

  30. Schaller M, Korting HC, Wolff H, Schirren CG, Burgdorf W (1996) Multiple keratoacanthomas, giant keratoacanthoma and keratoacanthoma centrifugum marginatum: development in a single patient and treatment with oral isotretinoin. Acta Derm Venereol 76(1):40–42

    CAS  PubMed  Google Scholar 

  31. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R et al (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315(24):1501–1505

    CAS  PubMed  Google Scholar 

  32. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL (1988) Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 318(25):1633–1637

    CAS  PubMed  Google Scholar 

  33. Saade M, Debahy NE, Houjeily S (1999) Clinical remission of xeroderma pigmentosum-associated squamous cell carcinoma with isotretinoin and chemotherapy: case report. J Chemother 11(4):313–317

    CAS  PubMed  Google Scholar 

  34. Zaman S, Gillani JA, Nabeela N, Khattak R, Iqbal I, Ul-Ain N et al (2014) Role of isotretinoin in cancer prevention and management in malignancies associated with xeroderma pigmentosum. J Ayub Med Coll Abbottabad 26(2):255–257

    PubMed  Google Scholar 

  35. Moon TE, Levine N, Cartmel B, Bangert JL (1997) Retinoids in prevention of skin cancer. Cancer Lett 114(1–2):203–205

    CAS  PubMed  Google Scholar 

  36. Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q et al (1997) Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomark Prev. 6(11):957–961

    CAS  Google Scholar 

  37. Kraemer KH, DiGiovanna JJ, Peck GL (1992) Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol 19(11):715–718

    CAS  PubMed  Google Scholar 

  38. Bagatin E, Guadanhim LR, Enokihara MM, Sanudo A, Talarico S, Miot HA et al (2014) Low-dose oral isotretinoin versus topical retinoic acid for photoaging: a randomized, comparative study. Int J Dermatol 53(1):114–122

    CAS  PubMed  Google Scholar 

  39. Bagatin E, Parada MO, Miot HA, Hassun KM, Michalany N, Talarico S (2010) A randomized and controlled trial about the use of oral isotretinoin for photoaging. Int J Dermatol 49(2):207–214

    CAS  PubMed  Google Scholar 

  40. Hernandez-Perez E, Khawaja HA, Alvarez TY (2000) Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol Surg 26(7):649–652

    CAS  PubMed  Google Scholar 

  41. Rabello-Fonseca RM, Azulay DR, Luiz RR, Mandarim-de-Lacerda CA, Cuzzi T, Manela-Azulay M (2009) Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication. J Eur Acad Dermatol Venereol 23(2):115–123

    CAS  PubMed  Google Scholar 

  42. Ianhez M, Pinto SA, Miot HA, Bagatin E (2019) A randomized, open, controlled trial of tretinoin 0.05% cream vs low-dose oral isotretinoin for the treatment of field cancerization. Int J Dermatol. 58(3):365–373

    CAS  PubMed  Google Scholar 

  43. Bravo BS, Azulay DR, Luiz RR, Mandarim-De-Lacerda CA, Cuzzi T, Azulay MM (2015) Oral isotretinoin in photoaging: objective histological evidence of efficacy and durability. An Bras Dermatol 90(4):479–486

    PubMed  PubMed Central  Google Scholar 

  44. Sander CA, Pfeiffer C, Kligman AM, Plewig G (1997) Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 36(2 Pt 1):236–238

    CAS  PubMed  Google Scholar 

  45. Kalil CL, Fachinello FZ, Lamb FM, Comunello LN (2008) Use of oral isotretinoin in photoaging therapy. Skinmed 7(1):10–14

    PubMed  Google Scholar 

  46. Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ et al (1992) Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst. 84(5):328–332

    CAS  PubMed  Google Scholar 

  47. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF et al (1996) Combined modality therapy for cutaneous T cell lymphoma. J Am Acad Dermatol 34(6):1022–1029

    CAS  PubMed  Google Scholar 

  48. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R (2003) Analysis of long-term outcomes of combined modality therapy for cutaneous T cell lymphoma. J Am Acad Dermatol 49(1):35–49

    PubMed  Google Scholar 

  49. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M (1991) Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 24(2 Pt 1):247–252

    CAS  PubMed  Google Scholar 

  50. Amitay-Laish I, Reiter O, Prag-Naveh H, Kershenovich R, Hodak E (2019) Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work? J Dermatolog Treat 30(3):258–263

    CAS  PubMed  Google Scholar 

  51. Thomsen K (1995) Cutaneous T cell lymphoma and calcitriol and isotretinoin treatment. Lancet 345(8964):1583

    CAS  PubMed  Google Scholar 

  52. Su IJ, Cheng AL, Tsai TF, Lay JD (1993) Retinoic acid-induced apoptosis and regression of a refractory Epstein-Barr virus-containing T cell lymphoma expressing multidrug-resistance phenotypes. Br J Haematol 85(4):826–828

    CAS  PubMed  Google Scholar 

  53. Wantzin GL, Thomsen K (1985) A new cutaneous side effect of isotretinoin. J Am Acad Dermatol 13(4):665

    CAS  PubMed  Google Scholar 

  54. Warrell RP Jr, Coonley CJ, Kempin SJ, Myskowski P, Safai B, Itri LM (1983) Isotretinoin in cutaneous T cell lymphoma. Lancet 2(8350):629

    PubMed  Google Scholar 

  55. Neely SM, Mehlmauer M, Feinstein DI (1987) The effect of isotretinoin in six patients with cutaneous T cell lymphoma. Arch Intern Med 147(3):529–531

    CAS  PubMed  Google Scholar 

  56. Molin L, Thomsen K, Volden G, Aronsson A, Hammar H, Hellbe L et al (1987) Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 67(3):232–236

    CAS  PubMed  Google Scholar 

  57. Thomsen K, Molin L, Volden G, Lange Wantzin G, Hellbe L (1984) 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 64(6):563–566

    CAS  PubMed  Google Scholar 

  58. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr (1987) Isotretinoin and cutaneous helper T cell lymphoma (mycosis fungoides). Arch Dermatol 123(2):201–204

    CAS  PubMed  Google Scholar 

  59. Thomsen K, Hammar H, Molin L, Volden G (1989) Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 69(6):536–538

    CAS  PubMed  Google Scholar 

  60. Fitzpatrick JE, Mellette JR (1986) Treatment of mycosis fungoides with isotretinoin. J Dermatol Surg Oncol 12(6):626–629

    CAS  PubMed  Google Scholar 

  61. Leverkus M, Rose C, Brocker EB, Goebeler M (2005) Follicular cutaneous T cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones. Br J Dermatol 152(1):193–194

    CAS  PubMed  Google Scholar 

  62. Kessler JF, Meyskens FL Jr, Levine N, Lynch PJ, Jones SE (1983) Treatment of cutaneous T cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1(8338):1345–1347

    CAS  PubMed  Google Scholar 

  63. Zhang C, Duvic M (2006) Treatment of cutaneous T cell lymphoma with retinoids. Dermatol Ther 19(5):264–271

    CAS  PubMed  Google Scholar 

  64. Ertl GA, Levine N, Kligman AM (1994) A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 130(3):319–324

    CAS  PubMed  Google Scholar 

  65. Gollnick H, Blume-Peytavi U, Szabo EL, Meyer KG, Hauptmann P, Popp G et al (2010) Systemic isotretinoin in the treatment of rosacea—doxycycline- and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges 8(7):505–515

    PubMed  Google Scholar 

  66. Sbidian E, Vicaut E, Chidiack H, Anselin E, Cribier B, Dreno B et al (2016) A Randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol 136(6):1124–1129

    CAS  PubMed  Google Scholar 

  67. Bostanci O, Borelli C, Schaller M (2010) Treatment of extrafacial rosacea with low-dose isotretinoin. Acta Derm Venereol 90(4):409–410

    PubMed  Google Scholar 

  68. Debroy Kidambi A, Tiffin NJ, Ramsay HM (2016) Atypical rosacea in a male patient: case study. Dermatol Online J 22(2)

  69. Marsden JR, Shuster S, Neugebauer M (1984) Response of rosacea to isotretinoin. Clin Exp Dermatol 9(5):484–488

    CAS  PubMed  Google Scholar 

  70. Schmidt JB, Gebhart W, Raff M, Spona J (1984) 13-cis-Retinoic acid in rosacea. Clinical and laboratory findings. Acta Derm Venereol. 64(1):15–21

    CAS  PubMed  Google Scholar 

  71. Turjanmaa K, Reunala T (1987) Isotretinoin treatment of rosacea. Acta Derm Venereol 67(1):89–91

    CAS  PubMed  Google Scholar 

  72. Uslu M, Savk E, Karaman G, Sendur N (2012) Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements. Acta Derm Venereol 92(1):73–77

    CAS  PubMed  Google Scholar 

  73. Wee JS, Tan KB (2017) Phymatous rosacea presenting with leonine facies and clinical response to isotretinoin. Australas J Dermatol 58(1):72–73

    PubMed  Google Scholar 

  74. Erdogan FG, Yurtsever P, Aksoy D, Eskioglu F (1998) Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea. Arch Dermatol 134(7):884–885

    CAS  PubMed  Google Scholar 

  75. Hoting E, Paul E, Plewig G (1986) Treatment of rosacea with isotretinoin. Int J Dermatol 25(10):660–663

    CAS  PubMed  Google Scholar 

  76. Rademaker M (2018) Very low-dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients. Australas J Dermatol 59(1):26–30

    PubMed  Google Scholar 

  77. Kwon HH, Jung JY, Lee WY, Bae Y, Park GH (2019) Combined treatment of recalcitrant papulopustular rosacea involving pulsed dye laser and fractional microneedling radiofrequency with low-dose isotretinoin. J Cosmet Dermatol 19:105–111

    PubMed  Google Scholar 

  78. McFalda WL, Roebuck HL (2011) Rational management of papulopustular rosacea with concomitant facial seborrheic dermatitis: a case report. J Clin Aesthet Dermatol 4(1):40–42

    PubMed  PubMed Central  Google Scholar 

  79. Marquis K, Christensen LC, Rajpara A (2017) Dissecting cellulitis of the scalp with excellent response to isotretinoin. Pediatr Dermatol 34(4):e210–e211

    PubMed  Google Scholar 

  80. Badaoui A, Reygagne P, Cavelier-Balloy B, Pinquier L, Deschamps L, Crickx B et al (2016) Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature. Br J Dermatol 174(2):421–423

    CAS  PubMed  Google Scholar 

  81. Lee CN, Chen W, Hsu CK, Weng TT, Lee JY, Yang CC (2018) Dissecting folliculitis (dissecting cellulitis) of the scalp: a 66-patient case series and proposal of classification. J Dtsch Dermatol Ges 16(10):1219–1226

    PubMed  Google Scholar 

  82. Mundi JP, Marmon S, Fischer M, Kamino H, Patel R, Shapiro J (2012) Dissecting cellulitis of the scalp. Dermatol Online J 18(12):8

    PubMed  Google Scholar 

  83. Mihic LL, Tomas D, Situm M, Krolo I, Sebetic K, Sjerobabski-Masnec I et al (2011) Perifolliculitis capitis abscedens et suffodiens in a caucasian: diagnostic and therapeutic challenge. Acta Dermatovenerol Croat 19(2):98–102

    PubMed  Google Scholar 

  84. Scerri L, Williams HC, Allen BR (1996) Dissecting cellulitis of the scalp: response to isotretinoin. Br J Dermatol 134(6):1105–1108

    CAS  PubMed  Google Scholar 

  85. Georgala S, Korfitis C, Ioannidou D, Alestas T, Kylafis G, Georgala C (2008) Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: case reports. Cutis 82(3):195–198

    PubMed  Google Scholar 

  86. Hintze JM, Howard BE, Donald CB, Hayden RE (2016) Surgical management and reconstruction of Hoffman’s disease (dissecting cellulitis of the scalp). Case Rep Surg 2016:2123037

    PubMed  PubMed Central  Google Scholar 

  87. Khaled A, Zeglaoui F, Zoghlami A, Fazaa B, Kamoun MR (2007) Dissecting cellulitis of the scalp: response to isotretinoin. J Eur Acad Dermatol Venereol 21(10):1430–1431

    CAS  PubMed  Google Scholar 

  88. Koca R, Altinyazar HC, Ozen OI, Tekin NS (2002) Dissecting cellulitis in a white male: response to isotretinoin. Int J Dermatol 41(8):509–513

    PubMed  Google Scholar 

  89. Segurado-Miravalles G, Camacho-Martinez FM, Arias-Santiago S, Serrano-Falcon C, Serrano-Ortega S, Rodrigues-Barata R et al (2017) Epidemiology, clinical presentation and therapeutic approach in a multicentre series of dissecting cellulitis of the scalp. J Eur Acad Dermatol Venereol 31(4):e199–e200

    CAS  PubMed  Google Scholar 

  90. Wollina U, Gemmeke A, Koch A (2012) Dissecting cellulitis of the scalp responding to intravenous tumor necrosis factor-alpha antagonist. J Clin Aesthet Dermatol 5(4):36–39

    PubMed  PubMed Central  Google Scholar 

  91. Bachynsky T, Antonyshyn OM, Ross JB (1992) Dissecting folliculitis of the scalp. A case report of combined treatment using tissue expansion, radical excision, and isotretinoin. J Dermatol Surg Oncol. 18(10):877–880

    CAS  PubMed  Google Scholar 

  92. Stites PC, Boyd AS (2001) Dissecting cellulitis in a white male: a case report and review of the literature. Cutis 67(1):37–40

    CAS  PubMed  Google Scholar 

  93. Ellis CN, Krach KJ (2001) Uses and complications of isotretinoin therapy. J Am Acad Dermatol 45(5):S150–S157

    CAS  PubMed  Google Scholar 

  94. Schleicher SM, Milstein HJ (1985) Resolution of disseminated granuloma annulare following isotretinoin therapy. Cutis 36(2):147–148

    CAS  PubMed  Google Scholar 

  95. Schleicher SM, Milstein HJ, Lim SJ, Stanton CD (1992) Resolution of disseminated granuloma annulare with isotretinoin. Int J Dermatol 31(5):371–372

    CAS  PubMed  Google Scholar 

  96. Ratnavel RC, Norris PG (1995) Perforating granuloma annulare: response to treatment with isotretinoin. J Am Acad Dermatol 32(1):126–127

    CAS  PubMed  Google Scholar 

  97. Tang WY, Chong LY, Lo KK (1996) Resolution of generalized granuloma annulare with isotretinoin therapy. Int J Dermatol 35(6):455–456

    CAS  PubMed  Google Scholar 

  98. Young HS, Coulson IH (2000) Granuloma annulare following waxing induced pseudofolliculitis-resolution with isotretinoin. Clin Exp Dermatol 25(4):274–276

    CAS  PubMed  Google Scholar 

  99. Erkek E, Karaduman A, Bukulmez G, Senturk N, Ozkaya O (2001) An unusual form of generalized granuloma annulare in a patient with insulin-dependent diabetes mellitus. Acta Derm Venereol. 81(1):48–50

    CAS  PubMed  Google Scholar 

  100. Adams DC, Hogan DJ (2002) Improvement of chronic generalized granuloma annulare with isotretinoin. Arch Dermatol 138(11):1518–1519

    PubMed  Google Scholar 

  101. Arroyo MP (2003) Generalized granuloma annulare. Dermatol Online J 9(4):13

    PubMed  Google Scholar 

  102. Buendia-Eisman A, Ruiz-Villaverde R, Blasco-Melguizo J, Serrano-Ortega S (2003) Generalized annular granuloma: response to isotretinoin. Int J Dermatol 42(4):321–322

    PubMed  Google Scholar 

  103. Pasmatzi E, Georgiou S, Monastirli A, Tsambaos D (2005) Temporary remission of disseminated granuloma annulare under oral isotretinoin therapy. Int J Dermatol 44(2):169–171

    PubMed  Google Scholar 

  104. Sahin MT, Turel-Ermertcan A, Ozturkcan S, Turkdogan P (2006) Generalized granuloma annulare in a patient with type II diabetes mellitus: successful treatment with isotretinoin. J Eur Acad Dermatol Venereol 20(1):111–114

    CAS  PubMed  Google Scholar 

  105. Baskan EB, Turan A, Tunali S (2007) A case of generalized granuloma annulare with myelodysplastic syndrome: successful treatment with systemic isotretinoin and topical pimecrolimus 1% cream combination. J Eur Acad Dermatol Venereol 21(5):693–695

    CAS  PubMed  Google Scholar 

  106. Clayton BD, Jorizzo JL, Hitchcock MG, Fleischer AB, Williford PM, Feldman SR et al (1997) Adult pityriasis rubra pilaris: a 10-year case series. J Am Acad Dermatol 36(6 Pt 1):959–964

    CAS  PubMed  Google Scholar 

  107. Borok M, Lowe NJ (1990) Pityriasis rubra pilaris. Further observations of systemic retinoid therapy. J Am Acad Dermatol 22(5 Pt 1):792–795

    CAS  PubMed  Google Scholar 

  108. Dicken CH (1994) Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol 31(6):997–999

    CAS  PubMed  Google Scholar 

  109. Marrouche N, Kurban M, Kibbi AG, Abbas O (2014) Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon. Int J Dermatol 53(4):434–439

    PubMed  Google Scholar 

  110. Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH (2002) Pityriasis rubra pilaris in children. J Am Acad Dermatol 47(3):386–389

    PubMed  Google Scholar 

  111. Dicken CH (1987) Isotretinoin treatment of pityriasis rubra pilaris. J Am Acad Dermatol 16(2 Pt 1):297–301

    CAS  PubMed  Google Scholar 

  112. Gilgor RS, Chiaramonti A, Goldsmith LA, Lazarus GS (1980) Evaluation of 13-cis retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier’s disease. Cutis 25(4):380–381

    CAS  PubMed  Google Scholar 

  113. Goldsmith LA, Weinrich AE, Shupack J (1982) Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 6(4 Pt 2 Suppl):710–715

    CAS  PubMed  Google Scholar 

  114. Peck GL, Yoder FW, Olsen TG, Pandya MD, Butkus D (1978) Treatment of Darier’s disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne, and basal cell carcinoma with oral 13-cis-retinoic acid. Dermatologica 157(Suppl 1):11–12

    PubMed  Google Scholar 

  115. Risch J, Ashton RE, Lowe NJ, Chalet M (1984) 13-cis-retinoic acid for dyskeratinizing diseases–clinicopathological responses. Clin Exp Dermatol 9(5):472–483

    CAS  PubMed  Google Scholar 

  116. Sehgal VN, Srivastava G, Aggarwal AK, Sardana K, Jain M (2006) Efficacy of isotretinoin in pityriasis rubra pilaris: unapproved use. Int J Dermatol 45(10):1238–1240

    CAS  PubMed  Google Scholar 

  117. Akyol M, Ozcelik S (2005) Non-acne dermatologic indications for systemic isotretinoin. Am J Clin Dermatol 6(3):175–184

    PubMed  Google Scholar 

  118. Cardamakis E, Kotoulas IG, Relakis K, Metalinos K, Michopoulos J, Stathopoulos E et al (1995) Comparative study of systemic interferon alfa-2a plus isotretinoin versus isotretinoin in the treatment of recurrent condyloma acuminatum in men. Urology 45(5):857–860

    CAS  PubMed  Google Scholar 

  119. Cardamakis EK, Kotoulas IG, Dimopoulos DP, Stathopoulos EN, Michopoulos JT, Tzingounis VA (1996) Comparative study of systemic interferon alfa-2a with oral isotretinoin and oral isotretinoin alone in the treatment of recurrent condylomata accuminata. Arch Gynecol Obstet 258(1):35–41

    CAS  PubMed  Google Scholar 

  120. Georgala S, Katoulis AC, Georgala C, Bozi E, Mortakis A (2004) Oral isotretinoin in the treatment of recalcitrant condylomata acuminata of the cervix: a randomised placebo controlled trial. Sex Transm Infect 80(3):216–218

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Olsen EA, Kelly FF, Vollmer RT, Buddin DA, Weck PK (1989) Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminata. J Am Acad Dermatol 20(6):1023–1030

    CAS  PubMed  Google Scholar 

  122. Tsambaos D, Georgiou S, Monastirli A, Sakkis T, Sagriotis A, Goerz G (1997) Treatment of condylomata acuminata with oral isotretinoin. J Urol 158(5):1810–1812

    CAS  PubMed  Google Scholar 

  123. Jha AK, Sonthalia S, Ganguly S (2018) Oral isotretinoin as an adjunctive treatment for recurrent genital warts. J Am Acad Dermatol 78(2):e35–e36

    PubMed  Google Scholar 

  124. Pasmatzi E, Kapranos N, Monastirli A, Melachrinou M, Georgiou S, Tsambaos D (2012) Large benign condyloma acuminatum: successful treatment with isotretinoin and interferon alpha. Acta Derm Venereol 92(3):249–250

    CAS  PubMed  Google Scholar 

  125. Yew YW, Pan JY (2014) Complete remission of recalcitrant genital warts with a combination approach of surgical debulking and oral isotretinoin in a patient with systemic lupus erythematosus. Dermatol Ther. 27(2):79–82

    PubMed  Google Scholar 

  126. Yildirim M, Inaloz HS, Baysal V, Kesici D, Candir O (2004) A case of condyloma acuminatum treated successfully with low-dose isotretinoin and interferon. Int J Clin Pract 58(9):889–891

    CAS  PubMed  Google Scholar 

  127. Patel N, McKenzie SA, Harview CL, Truong AK, Shi VY, Chen L et al (2019) Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. J Dermatolog Treat 26:1–3

    Google Scholar 

  128. Huang CM, Kirchhof MG (2017) A new perspective on isotretinoin treatment of hidradenitis suppurativa: a retrospective chart review of patient outcomes. Dermatology 233(2–3):120–125

    CAS  PubMed  Google Scholar 

  129. Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F et al (2009) Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients’ outcome assessment. Dermatology 218(2):134–135

    CAS  PubMed  Google Scholar 

  130. Dicken CH, Powell ST, Spear KL (1984) Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol 11(3):500–502

    CAS  PubMed  Google Scholar 

  131. Jones DH, Cunliffe WJ, King K (1982) Hidradenitis suppurativa-lack of success with 13-cis-retinoic acid. Br J Dermatol 107(2):252

    PubMed  Google Scholar 

  132. Norris JF, Cunliffe WJ (1986) Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol 11(6):579–583

    CAS  PubMed  Google Scholar 

  133. Ornelas J, Sivamani R, Awasthi S (2016) A report of two patients with darier disease and hidradenitis suppurativa. Pediatr Dermatol 33(4):e265–e266

    PubMed  Google Scholar 

  134. Jorgensen AR, Thomsen SF, Ring HC (2019) Isotretinoin and hidradenitis suppurativa. Clin Exp Dermatol 44(4):e155–e156

    PubMed  Google Scholar 

  135. Burton CS, Sawchuk WS (1985) Premature sebaceous gland hyperplasia: successful treatment with isotretinoin. J Am Acad Dermatol 12(1 Pt 2):182–184

    CAS  PubMed  Google Scholar 

  136. Grimalt R, Ferrando J, Mascaro JM (1997) Premature familial sebaceous hyperplasia: successful response to oral isotretinoin in three patients. J Am Acad Dermatol 37(6):996–998

    CAS  PubMed  Google Scholar 

  137. Gupta V, Mridha AR, Sharma VK (2016) Sebaceous hyperplasia and sebaceous adenomas presenting as leonine facies and improving with oral isotretinoin. Clin Exp Dermatol 41(8):923–924

    CAS  PubMed  Google Scholar 

  138. Jung HY, Kim M, Cho BK, Park HJ (2016) A case of cyclosporine-induced sebaceous hyperplasia in a renal transplant patient successfully treated with isotretinoin. Ann Dermatol 28(2):271–272

    PubMed  PubMed Central  Google Scholar 

  139. Liu YS, Cheng YP, Liu CI, Yang CY, Yang CY (2016) Presenile diffuse familial sebaceous hyperplasia successfully treated with low-dose isotretinoin: a report of two cases and review of the published work. J Dermatol 43(10):1205–1208

    PubMed  Google Scholar 

  140. McDonald SK, Goh MS, Chong AH (2011) Successful treatment of cyclosporine-induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients. Australas J Dermatol 52(3):227–230

    PubMed  Google Scholar 

  141. Noh S, Shin JU, Jung JY, Lee JH (2014) A case of sebaceous hyperplasia maintained on low-dose isotretinoin after carbon dioxide laser treatment. Int J Dermatol 53(2):e151–e153

    PubMed  Google Scholar 

  142. Tagliolatto S, Santos Neto-Ode O, Alchorne MM, Enokihara MY (2015) Sebaceous hyperplasia: systemic treatment with isotretinoin. An Bras Dermatol. 90(2):211–215

    PubMed  PubMed Central  Google Scholar 

  143. Wang W, Qiu Y, Zhou G, Pei Z, Zhang F (2016) Premature sebaceous hyperplasia with satisfactory response to oral isotretinoin. Indian J Dermatol Venereol Leprol. 82(1):113

    PubMed  Google Scholar 

  144. Sehgal VN, Srivastava G (2005) Darier’s (Darier-White) disease/keratosis follicularis. Int J Dermatol 44(3):184–192

    PubMed  Google Scholar 

  145. Takagi A, Kamijo M, Ikeda S (2016) Darier disease. J Dermatol 43(3):275–279

    CAS  PubMed  Google Scholar 

  146. Del Rosso JQ, Horowitz DC (1986) Treatment of Darier’s disease with isotretinoin: report of a case. J Am Osteopath Assoc 86(10):634–638

    PubMed  Google Scholar 

  147. Kim C, Fangman W (2007) Keratosis follicularis (Darier-White disease), with an unusual palmoplantar keratoderma. Dermatol Online J 13(1):7

    PubMed  Google Scholar 

  148. Udayashankar C, Nath AK, Anuradha P (2013) Extensive Darier’s disease with pityriasis amiantacea, alopecia and congenital facial nerve palsy. Dermatol Online J 19(6):18574

    PubMed  Google Scholar 

  149. Rotunda AM, Cotliar J, Haley JC, Craft N (2005) Unilateral Darier’s disease associated with migraine headache responsive to isotretinoin. J Am Acad Dermatol 52(1):175–176

    PubMed  Google Scholar 

  150. Dicken CH, Bauer EA, Hazen PG, Krueger GG, Marks JG Jr, McGuire JS et al (1982) Isotretinoin treatment of Darier’s disease. J Am Acad Dermatol. 6(4 Pt 2 Suppl):721–726

    CAS  PubMed  Google Scholar 

  151. Gahalaut P, Soodan PS, Mishra N, Rastogi MK, Soodan HS, Chauhan S (2014) Clinical efficacy of psoralen + sunlight vs combination of isotretinoin and psoralen + sunlight for the treatment of chronic plaque-type psoriasis vulgaris: a randomized hospital-based study. Photodermatol Photoimmunol Photomed. 30(6):294–301

    CAS  PubMed  Google Scholar 

  152. Mortazavi H, Khezri S, Hosseini H, Khezri F, Vasigh M (2011) A single blind randomized clinical study: the efficacy of isotretinoin plus narrow band ultraviolet B in the treatment of psoriasis vulgaris. Photodermatol Photoimmunol Photomed 27(3):159–161

    PubMed  Google Scholar 

  153. Al-Shobaili H, Al-Khenaizan S (2007) Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol. 24(5):563–564

    PubMed  Google Scholar 

  154. Anstey A, Hawk JL (1997) Isotretinoin-PUVA in women with psoriasis. Br J Dermatol 136(5):798–799

    CAS  PubMed  Google Scholar 

  155. Honigsmann H, Wolff K (1983) Isotretinoin-PUVA for psoriasis. Lancet 1(8318):236

    CAS  PubMed  Google Scholar 

  156. Sofen HL, Moy RL, Lowe NJ (1984) Treatment of generalised pustular psoriasis with isotretinoin. Lancet 1(8367):40

    CAS  PubMed  Google Scholar 

  157. Wilken R, Sharma A, Patel F, Maverakis E (2015) Successful treatment of palmoplantar pustulosis with isotretinoin. Dermatol Online J 21(8)

  158. Moy RL, Kingston TP, Lowe NJ (1985) Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis. Arch Dermatol 121(10):1297–1301

    CAS  PubMed  Google Scholar 

  159. Okon L, Werth V (2013) Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol 27(3):391–404

    CAS  PubMed  PubMed Central  Google Scholar 

  160. Furner BB (1990) Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 29(8):587–590

    CAS  PubMed  Google Scholar 

  161. Fabbri P, Cardinali C, Giomi B, Caproni M (2003) Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 4(7):449–465

    PubMed  Google Scholar 

  162. Newton RC, Jorizzo JL, Solomon AR Jr, Sanchez RL, Daniels JC, Bell JD et al (1986) Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 122(2):170–176

    CAS  PubMed  Google Scholar 

  163. Rubenstein DJ, Huntley AC (1986) Keratotic lupus erythematosus: treatment with isotretinoin. J Am Acad Dermatol 14(5 Pt 2):910–914

    CAS  PubMed  Google Scholar 

  164. Green SG, Piette WW (1987) Successful treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol 17(2 Pt 2):364–368

    CAS  PubMed  Google Scholar 

  165. Shornick JK, Formica N, Parke AL (1991) Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 24(1):49–52

    CAS  PubMed  Google Scholar 

  166. Richardson TT, Cohen PR (2000) Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin. Cutis 66(3):183–188

    CAS  PubMed  Google Scholar 

  167. D’Erme AM, Milanesi N, Difonzo EM, Lotti T, Gola M (2012) Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option. Dermatol Ther 25(3):281–282

    PubMed  Google Scholar 

  168. Olguin-Garcia MG, Jurado-Santa Cruz F, Peralta-Pedrero ML, Morales-Sanchez MA (2015) A double-blind, randomized, placebo-controlled trial of oral isotretinoin in the treatment of recalcitrant facial flat warts. J Dermatolog Treat 26(1):78–82

    CAS  PubMed  Google Scholar 

  169. Kaur GJ, Brar BK, Kumar S, Brar SK, Singh B (2017) Evaluation of the efficacy and safety of oral isotretinoin versus topical isotretinoin in the treatment of plane warts: a randomized open trial. Int J Dermatol 56(12):1352–1358

    CAS  PubMed  Google Scholar 

  170. Al-Hamamy HR, Salman HA, Abdulsattar NA (2012) Treatment of plane warts with a low-dose oral isotretinoin. ISRN Dermatol 2012:163929

    PubMed  PubMed Central  Google Scholar 

  171. Miljkovic J (2012) A novel therapeutic approach to plane warts: a report on two cases. Acta Dermatovenerol Alp Pannonica Adriat 21(3):63–64

    PubMed  Google Scholar 

  172. Bialecka A, Mecinska-Jundzill K, Adamska U, Cichewicz A, Bialecki M, Drewa G et al (2018) Plane warts on the back of the hand successfully treated with oral isotretinoin. Postepy Dermatol Alergol 35(2):227–229

    PubMed  PubMed Central  Google Scholar 

  173. Dave DD, Abdelmaksoud A (2019) Low dose isotretinoin as an adjuvant therapy for treatment of different clinical variants of warts: a case series. Dermatol Ther 32(2):e12836

    PubMed  Google Scholar 

  174. Tietze JK, Heppt MV, von Preussen A, Wolf U, Ruzicka T, Wolff H et al (2015) Oral isotretinoin as the most effective treatment in folliculitis decalvans: a retrospective comparison of different treatment regimens in 28 patients. J Eur Acad Dermatol Venereol 29(9):1816–1821

    CAS  PubMed  Google Scholar 

  175. Aksoy B, Hapa A, Mutlu E (2018) Isotretinoin treatment for folliculitis decalvans: a retrospective case-series study. Int J Dermatol 57(2):250–253

    CAS  PubMed  Google Scholar 

  176. Bunagan MJ, Banka N, Shapiro J (2015) Retrospective review of folliculitis decalvans in 23 patients with course and treatment analysis of long-standing cases. J Cutan Med Surg. 19(1):45–49

    PubMed  Google Scholar 

  177. Miguel-Gomez L, Rodrigues-Barata AR, Molina-Ruiz A, Martorell-Calatayud A, Fernandez-Crehuet P, Grimalt R et al (2018) Folliculitis decalvans: effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-up. J Am Acad Dermatol 79(5):878–883

    PubMed  Google Scholar 

  178. Shireen F, Sudhakar A (2018) A case of isotretinoin therapy-refractory folliculitis decalvans treated successfully with biosimilar adalimumab (exemptia). Int J Trichol 10(5):240–241

    Google Scholar 

  179. Gemmeke A, Wollina U (2006) Folliculitis decalvans of the scalp: response to triple therapy with isotretinoin, clindamycin, and prednisolone. Acta Dermatovenerol Alp Pannonica Adriat 15(4):184–186

    PubMed  Google Scholar 

  180. Babahosseini H, Tavakolpour S, Mahmoudi H, Balighi K, Teimourpour A, Ghodsi SZ et al (2019) Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. J Dermatolog Treat 30(6):598–604

    CAS  PubMed  Google Scholar 

  181. Mardones F, Shapiro J (2017) Lichen planopilaris in a Latin American (Chilean) population: demographics, clinical profile and treatment experience. Clin Exp Dermatol 42(7):755–759

    CAS  PubMed  Google Scholar 

  182. Rakowska A, Gradzinska A, Olszewska M, Rudnicka L (2017) Efficacy of isotretinoin and acitretin in treatment of frontal fibrosing alopecia: retrospective analysis of 54 cases. J Drugs Dermatol 16(10):988–992

    CAS  PubMed  Google Scholar 

  183. Pham CT, Hosking AM, Cox S, Mesinkovska NA (2020) Therapeutic response of facial papules and inflammation in frontal fibrosing alopecia to low-dose oral isotretinoin. JAAD Case Rep 6(5):453–456

    PubMed  PubMed Central  Google Scholar 

  184. Pedrosa AF, Duarte AF, Haneke E, Correia O (2017) Yellow facial papules associated with frontal fibrosing alopecia: a distinct histologic pattern and response to isotretinoin. J Am Acad Dermatol 77(4):764–766

    PubMed  Google Scholar 

  185. Pirmez R, Duque-Estrada B, Barreto T, Quintella DC, Cuzzi T (2017) Successful treatment of facial papules in frontal fibrosing alopecia with oral isotretinoin. Skin Appendage Disord 3(2):111–113

    PubMed  PubMed Central  Google Scholar 

  186. Namazi N, Niknezhad N, Niknejad N, Asadi-Kani Z (2018) Familial facial lichen planopilaris and satisfactory response to isotretinoin. Dermatol Ther 31(5):e12633

    PubMed  Google Scholar 

  187. Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S (2016) Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol 55(9):1048–1054

    CAS  PubMed  Google Scholar 

  188. Handler HL (1984) Isotretinoin for oral lichen planus. J Am Acad Dermatol 10(4):674

    CAS  PubMed  Google Scholar 

  189. Camisa C, Allen CM (1986) Treatment of oral erosive lichen planus with systemic isotretinoin. Oral Surg Oral Med Oral Pathol 62(4):393–396

    CAS  PubMed  Google Scholar 

  190. Boyd AS, King LE (2001) Lichenoid drug reaction from isotretinoin therapy. Cutis 68(4):301–303

    CAS  PubMed  Google Scholar 

  191. Woo TY (1985) Systemic isotretinoin treatment of oral and cutaneous lichen planus. Cutis 35(4):385–386 (90–1, 93)

    CAS  PubMed  Google Scholar 

  192. Rigopoulos D, Larios G, Katsambas AD (2010) The role of isotretinoin in acne therapy: why not as first-line therapy? Facts and controversies. Clin Dermatol. 28(1):24–30

    PubMed  Google Scholar 

  193. Administration UFaD (2005) iPLEDGE program. Available from: http://www.ipledgeprogram.com/

  194. Lamberg L (1998) Acne drug depression warnings highlight need for expert care. JAMA 279(14):1057

    CAS  PubMed  Google Scholar 

Download references

Funding

The authors did not receive funding for this research.

Author information

Authors and Affiliations

  1. College of Osteopathic Medicine of the Pacific, Northwest, Western University of Health Sciences, 200 Mullins Dr., Lebanon, OR, 97355, USA

    Sherman Chu

  2. Department of Dermatology, University of California, Irvine, Irvine, CA, 92697, USA

    Sherman Chu, Lauren Michelle, Chloe Ekelem, Calvin T. Sung, Nathan Rojek & Natasha A. Mesinkovska

Authors
  1. Sherman Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lauren Michelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chloe Ekelem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Calvin T. Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nathan Rojek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Natasha A. Mesinkovska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sherman Chu.

Ethics declarations

Conflict of interest

The authors do not have any conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chu, S., Michelle, L., Ekelem, C. et al. Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions. Arch Dermatol Res 313, 391–430 (2021). https://doi.org/10.1007/s00403-020-02152-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-020-02152-4

Keywords

Search

Navigation